BPD (supplemental oxygen/respiratory support at 36 weeks' postmenstrual age if born < 32 weeks' gestation, or 28 days if born ≥ 32 weeks' gestation) · preterm infants requiring primary respiratory support
Nasal high flow showed no clear difference in BPD (supplemental oxygen/respiratory support at 36 weeks'… compared with continuous positive airway pressure (low certainty).
1 finding from 1 review
Death (before hospital discharge) or BPD (supplemental oxygen/respiratory support at 36 weeks' postmenstrual age if born < 32 weeks' gestation, or 28 days if born ≥ 32 weeks' gestation) · preterm infants requiring primary respiratory support
It is very uncertain whether nasal high flow changes death (before hospital discharge) or BPD (supplemental… compared with nasal intermittent positive pressure ventilation (very low certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · term and preterm infants resuscitated at birth, using positive pressure ventilation
Nasal interfaces (single nasal prong, binasal prongs (long or… showed no clear difference in the need for supplemental oxygen at 36 weeks' corrected gestational… compared with face mask (low certainty).
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Exercise capacity · people with pulmonary hypertension
1 finding from 1 review
BPD at 28 days · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes BPD defined as an oxygen requirement at 28 days№ of participants:… compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.94, 1.26]
Studies not reported
Very low
Bronchopulmonary dysplasia · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes BPD defined as oxygen at 36 weeks' postmenstrual age№ of… compared with placebo (very low certainty).
1 finding from 1 review
RR 0.96 [0.72, 1.29]
Studies not reported
Very low
Need for supplemental oxygen (days)№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
OXYGEN SATURATION DURING intervention (higher = favourable) · preterm infants and their parents
1 finding from 1 review
Intervention not reported
OXYGEN SATURATION POST‐intervention (higher = favourable) · preterm infants and their parents
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants at risk for apnea
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants with apnea
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants prior to extubation
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (high certainty).
1 finding from 1 review
Chronic lung disease · treatment of apnea
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
Caffeine showed no clear difference in bronchopulmonary dysplasia/chronic lung disease: defined as 28 days… compared with other methylxanthines (low certainty).
1 finding from 1 review
RR 1.4 [0.92, 2.11]
Studies not reported
Low
Oxygenation index (FiO2% X MPAW/PaO2) ‐ not reported · acute respiratory distress in hospitalised infants and children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Oxygen saturation (SaO2) ‐ not reported · acute respiratory distress in hospitalised infants and children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found